Xencor Inc (XNCR) Stock Analysis and Metrics

Xencor

NASDAQ: XNCR

$19.42 ▼ -0.11 (-0.54%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.47 Bn

P/E-8.54

P/S15.12

Div. Yield0.00

ROIC (Qtr)-0.01

Total Debt (Qtr)108.53 Mn

Revenue Growth (1y) (Qtr)-86.20

Add ratio to table…

About

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. The company leverages its protein engineering expertise to design XmAb drug candidates with improved properties such as bispecific structure and extended half-life. These candidates are advanced into clinical development to evaluate their potential for later stage development, partnership, or commercialization.

Xencor generates revenue primarily through licensing and collaboration agreements with pharmaceutical and biotechnology partners, which include upfront payments, milestone payments, and royalties on net sales of approved products. The company also earns royalties from three marketed medicines that were developed using its XmAb technology, such as Monjuvi and Ultomiris. Additionally, Xencor may receive research funding and other consideration from its collaborative arrangements.

Xencor occupies a niche position in the biopharmaceutical industry as a pioneer of Fc domain engineering, with a proprietary platform that enables the creation of multispecific antibodies and other engineered formats. Its competitors include large pharmaceutical companies and biotechnology firms such as Amgen, Genmab, Regeneron, Roche, Janssen, and Astellas, which are also developing bispecific antibody therapies. Xencor's competitive advantage lies in its modular XmAb technology, extensive patent estate covering thousands of Fc variants, and its ability to partner while retaining key rights to its leading programs.

Xencor's customer base consists of the pharmaceutical and biotechnology companies that license its technology or collaborate on drug development, as well as the patients who ultimately receive the partnered medicines. Specific collaborators and customers include Incyte, which markets Monjuvi; Zenas and its partner Bristol Myers Squibb, which develop obexelimab; Amgen, which advances xaluritamig; Astellas, which develops ASP2138; Janssen, which works on JNJ-9401 and JNJ-1493; Alexion, which commercializes Ultomiris; Vir Bio, Novo Nordisk, Gilead, and Novartis, which license various XmAb Fc domains for their own programs.

Investment Thesis

▲ Bull case

Xencor’s robust clinical pipeline progress positions it for meaningful near-term catalysts that could significantly de-risk its oncology and autoimmune programs. The Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma showed a 25% partial response rate among efficacy-evaluable patients with a 70% disease control rate, indicating early anti-tumor activity in a historically difficult-to-treat population. The ongoing dose-expansion portion of this study, coupled with planned data presentations in the second half of 2026, could provide stronger evidence of efficacy and support the initiation of a pivotal study in 2027 as management has indicated. This timeline aligns with the company’s guidance to have sufficient cash resources to fund operations through 2028, reducing near-term financing risk. The expansion into additional tumor types with high ENPP3 expression—colorectal, non-small cell lung, and papillary renal cell carcinomas—further broadens the addressable market for XmAb819 beyond its initial indication, creating optionality that is not yet fully reflected in current valuations.
The TL1A-focused autoimmune pipeline represents a differentiated and potentially best-in-class opportunity in inflammatory bowel disease, with XmAb942 demonstrating favorable pharmacokinetics in Phase 1, including a terminal half-life of 74.1 days supporting a convenient every-12-week subcutaneous dosing schedule. This dosing advantage could improve patient adherence and quality of life compared to more frequent regimens, a factor that is increasingly valued in chronic disease management. Strong investigator enthusiasm and on-track enrollment in the global Phase 2b XENITH-UC study—designed to enroll approximately 220 patients across active treatment and placebo arms—suggests high clinical interest and reduces execution risk. The planned blinded interim analysis around year-end 2026 and primary endpoint analysis in the second half of 2027 provide clear, near-term inflection points where positive data could trigger re-rating of the stock, particularly if XmAb942 shows superiority or non-inferiority to existing biologics in ulcerative colitis.
Xencor’s financial runway remains stronger than market perceptions suggest, despite recent headwinds from the Alexion royalty dispute. The company ended Q1 2026 with $541.8 million in cash, cash equivalents, and marketable debt securities, and maintains guidance to end 2026 with between $380 million and $400 million in liquidity, sufficient to fund operations into mid-2028. This outlook incorporates a conservative adjustment for the disputed U.S. Ultomiris royalties, yet still reflects multiple years of runway without needing additional dilutive financing. Furthermore, the company continues to receive low-single-digit royalties on ex-U.S. sales of Ultomiris, and the issued U.S. Patent 12,492,253—which extends into December 2028—provides a legal basis to pursue resolution of the payment dispute. Even if only a portion of the previously estimated $100–$120 million in aggregate U.S. royalties through 2028 is recovered, it would meaningfully extend the cash runway and reduce pressure on the balance sheet.
The XenLock™ Fab domain platform underlying XmAb412 represents a proprietary and scalable advancement in bispecific antibody engineering that could yield long-term value beyond the current clinical candidates. By enabling native-like, 1+1 format multi-specific antibodies with high affinity, stability, and low immunogenicity, XenLock™ addresses key manufacturability and developability challenges that have hampered earlier bispecific formats. XmAb412’s sub-picomolar affinity for IL23 and single-digit picomolar binding to TL1A, combined with its effector-less design and Xtend™ half-life extension, positions it as a potentially best-in-class candidate for dual-pathway inhibition in autoimmune disease. The planned first-in-human study in the Q3 FY26 will generate critical pharmacodynamic and safety data, and a successful outcome could validate the platform for broader application across Xencor’s pipeline or attract partnership interest, creating an underappreciated optionality factor in the current valuation.

Xencor’s robust clinical pipeline progress positions it for meaningful near-term catalysts that could significantly de-risk its oncology and autoimmune programs. The Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma showed a 25% partial response rate among efficacy-evaluable patients with a 70% disease control rate, indicating early anti-tumor activity in a historically difficult-to-treat population. The ongoing dose-expansion portion of this study, coupled with planned data presentations in the second half of 2026, could provide stronger evidence of efficacy and support the initiation of a pivotal study in 2027 as management has indicated. This timeline aligns with the company’s guidance to have sufficient cash resources to fund operations through 2028, reducing near-term financing risk. The expansion into additional tumor types with high ENPP3 expression—colorectal, non-small cell lung, and papillary renal cell carcinomas—further broadens the addressable market for XmAb819 beyond its initial indication, creating optionality that is not yet fully reflected in current valuations.
The TL1A-focused autoimmune pipeline represents a differentiated and potentially best-in-class opportunity in inflammatory bowel disease, with XmAb942 demonstrating favorable pharmacokinetics in Phase 1, including a terminal half-life of 74.1 days supporting a convenient every-12-week subcutaneous dosing schedule. This dosing advantage could improve patient adherence and quality of life compared to more frequent regimens, a factor that is increasingly valued in chronic disease management. Strong investigator enthusiasm and on-track enrollment in the global Phase 2b XENITH-UC study—designed to enroll approximately 220 patients across active treatment and placebo arms—suggests high clinical interest and reduces execution risk. The planned blinded interim analysis around year-end 2026 and primary endpoint analysis in the second half of 2027 provide clear, near-term inflection points where positive data could trigger re-rating of the stock, particularly if XmAb942 shows superiority or non-inferiority to existing biologics in ulcerative colitis.
Xencor’s financial runway remains stronger than market perceptions suggest, despite recent headwinds from the Alexion royalty dispute. The company ended Q1 2026 with $541.8 million in cash, cash equivalents, and marketable debt securities, and maintains guidance to end 2026 with between $380 million and $400 million in liquidity, sufficient to fund operations into mid-2028. This outlook incorporates a conservative adjustment for the disputed U.S. Ultomiris royalties, yet still reflects multiple years of runway without needing additional dilutive financing. Furthermore, the company continues to receive low-single-digit royalties on ex-U.S. sales of Ultomiris, and the issued U.S. Patent 12,492,253—which extends into December 2028—provides a legal basis to pursue resolution of the payment dispute. Even if only a portion of the previously estimated $100–$120 million in aggregate U.S. royalties through 2028 is recovered, it would meaningfully extend the cash runway and reduce pressure on the balance sheet.
The XenLock™ Fab domain platform underlying XmAb412 represents a proprietary and scalable advancement in bispecific antibody engineering that could yield long-term value beyond the current clinical candidates. By enabling native-like, 1+1 format multi-specific antibodies with high affinity, stability, and low immunogenicity, XenLock™ addresses key manufacturability and developability challenges that have hampered earlier bispecific formats. XmAb412’s sub-picomolar affinity for IL23 and single-digit picomolar binding to TL1A, combined with its effector-less design and Xtend™ half-life extension, positions it as a potentially best-in-class candidate for dual-pathway inhibition in autoimmune disease. The planned first-in-human study in the Q3 FY26 will generate critical pharmacodynamic and safety data, and a successful outcome could validate the platform for broader application across Xencor’s pipeline or attract partnership interest, creating an underappreciated optionality factor in the current valuation.

▼ Bear case

Xencor’s financial position is deteriorating more rapidly than acknowledged, with cash burn accelerating due to expanded clinical-stage spending and declining royalty income. The company reported a Q1 2026 net loss of $128.9 million—a significant increase from $48.4 million in the same period of 2025—driven in part by a $50.8 million other expense, net, primarily from unrealized losses on an equity security. While some of this volatility is non-cash, the underlying trend shows rising R&D expenses ($64.7 million in Q1 2026 vs. $58.6 million in Q1 2025) and stagnant G&A costs, indicating operating leverage is not improving. Revenue for Q1 2026 fell to $4.5 million from $32.7 million a year ago, reflecting the loss of milestone income and increased reliance on volatile non-cash royalty streams. With cash now at $541.8 million and guidance calling for an end-2026 balance of only $380–$400 million, the implied annual burn rate exceeds $150 million, putting pressure on the mid-2028 runway claim, especially if clinical costs rise faster than expected in later-stage trials.
The Alexion royalty dispute over U.S. sales of Ultomiris poses a material and underappreciated risk to Xencor’s long-term financial stability, with management’s conservative guidance already reflecting a reduced outlook. Although ex-U.S. royalties continue, the loss of U.S. payments—historically a major contributor due to Ultomiris’s dominant market share in the United States—could eliminate a significant portion of the previously modeled $100–$120 million in aggregate royalties through 2028. Even if the patent provides legal leverage, litigation or arbitration outcomes are uncertain and could take years, during which Xencor would forgo cash inflows while continuing to fund expensive clinical programs. The company’s acknowledgment that it has “updated year-end cash guidance” and “conservatively adjusted” its operating runway signals internal recognition of the severity, yet the market may not be fully pricing in the potential for a prolonged or unfavorable resolution that could force earlier-than-expected financing dilutive events.
Clinical progression risks remain high across Xencor’s pipeline, particularly for its flagship oncology candidate XmAb819, where early-phase signals may not translate to later-stage success. While the Phase 1 data showed a 25% partial response rate in ccRCC, this came from a small, dose-selected cohort of 20 efficacy-evaluable patients, and disease control rates—though 70%—include stable disease, which may not be sufficient to support regulatory approval without durable responses. The expansion into additional tumor types (colorectal, NSCLC, papillary RCC) spreads resources thin and increases complexity, yet there is no proof that ENPP3 expression correlates with response in these indications. Furthermore, the T-cell engager mechanism carries inherent risks of cytokine release syndrome and neurotoxicity, which could limit dosing or require intensive monitoring, reducing real-world usability. Without clear differentiation from existing or emerging therapies in these crowded oncology spaces, XmAb819 may fail to capture meaningful market share even if approved.
The autoimmune pipeline, while scientifically promising, faces steep competitive and regulatory hurdles that could delay or derail commercialization despite positive early data. XmAb942’s every-12-week dosing is an advantage, but it enters a crowded ulcerative colitis market dominated by established biologics like vedolizumab, ustekinumab, and newer agents such as mirikizumab and etrasimod, many of which have strong efficacy and safety profiles. Achieving non-inferiority, let alone superiority, in the Phase 2b XENITH-UC trial will be challenging, and the study’s design—enrolling patients who have failed conventional or advanced therapy—may select for a more refractory population, making endpoints harder to hit. Even if successful, the path to Phase 3 and approval is long, with the primary endpoint analysis not expected until the second half of 2027. XmAb412, while innovative, is earlier in development and faces similar risks: dual-targeting increases complexity, and there is no clinical proof yet that simultaneous TL1A and IL23p19 blockade offers additive or synergistic benefit over sequential or monotherapy approaches. The platform’s novelty also means manufacturing and immunogenicity risks are not fully characterized, which could delay timelines or increase costs beyond current estimates.

Xencor’s financial position is deteriorating more rapidly than acknowledged, with cash burn accelerating due to expanded clinical-stage spending and declining royalty income. The company reported a Q1 2026 net loss of $128.9 million—a significant increase from $48.4 million in the same period of 2025—driven in part by a $50.8 million other expense, net, primarily from unrealized losses on an equity security. While some of this volatility is non-cash, the underlying trend shows rising R&D expenses ($64.7 million in Q1 2026 vs. $58.6 million in Q1 2025) and stagnant G&A costs, indicating operating leverage is not improving. Revenue for Q1 2026 fell to $4.5 million from $32.7 million a year ago, reflecting the loss of milestone income and increased reliance on volatile non-cash royalty streams. With cash now at $541.8 million and guidance calling for an end-2026 balance of only $380–$400 million, the implied annual burn rate exceeds $150 million, putting pressure on the mid-2028 runway claim, especially if clinical costs rise faster than expected in later-stage trials.
The Alexion royalty dispute over U.S. sales of Ultomiris poses a material and underappreciated risk to Xencor’s long-term financial stability, with management’s conservative guidance already reflecting a reduced outlook. Although ex-U.S. royalties continue, the loss of U.S. payments—historically a major contributor due to Ultomiris’s dominant market share in the United States—could eliminate a significant portion of the previously modeled $100–$120 million in aggregate royalties through 2028. Even if the patent provides legal leverage, litigation or arbitration outcomes are uncertain and could take years, during which Xencor would forgo cash inflows while continuing to fund expensive clinical programs. The company’s acknowledgment that it has “updated year-end cash guidance” and “conservatively adjusted” its operating runway signals internal recognition of the severity, yet the market may not be fully pricing in the potential for a prolonged or unfavorable resolution that could force earlier-than-expected financing dilutive events.
Clinical progression risks remain high across Xencor’s pipeline, particularly for its flagship oncology candidate XmAb819, where early-phase signals may not translate to later-stage success. While the Phase 1 data showed a 25% partial response rate in ccRCC, this came from a small, dose-selected cohort of 20 efficacy-evaluable patients, and disease control rates—though 70%—include stable disease, which may not be sufficient to support regulatory approval without durable responses. The expansion into additional tumor types (colorectal, NSCLC, papillary RCC) spreads resources thin and increases complexity, yet there is no proof that ENPP3 expression correlates with response in these indications. Furthermore, the T-cell engager mechanism carries inherent risks of cytokine release syndrome and neurotoxicity, which could limit dosing or require intensive monitoring, reducing real-world usability. Without clear differentiation from existing or emerging therapies in these crowded oncology spaces, XmAb819 may fail to capture meaningful market share even if approved.
The autoimmune pipeline, while scientifically promising, faces steep competitive and regulatory hurdles that could delay or derail commercialization despite positive early data. XmAb942’s every-12-week dosing is an advantage, but it enters a crowded ulcerative colitis market dominated by established biologics like vedolizumab, ustekinumab, and newer agents such as mirikizumab and etrasimod, many of which have strong efficacy and safety profiles. Achieving non-inferiority, let alone superiority, in the Phase 2b XENITH-UC trial will be challenging, and the study’s design—enrolling patients who have failed conventional or advanced therapy—may select for a more refractory population, making endpoints harder to hit. Even if successful, the path to Phase 3 and approval is long, with the primary endpoint analysis not expected until the second half of 2027. XmAb412, while innovative, is earlier in development and faces similar risks: dual-targeting increases complexity, and there is no clinical proof yet that simultaneous TL1A and IL23p19 blockade offers additive or synergistic benefit over sequential or monotherapy approaches. The platform’s novelty also means manufacturing and immunogenicity risks are not fully characterized, which could delay timelines or increase costs beyond current estimates.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password